Preferred Label : Xirestomig;
NCIt synonyms : Anti-PD-L1/Anti-4-1BB Bispecific Antibody ATG-101; PD-L1 x 4-1BB Bispecific Antibody ATG-101; Anti-PD-L1/CD137 Bispecific Antibody ATG-101; Anti-PD-L1/4-1BB Bispecific Antibody ATG-101;
NCIt definition : A bispecific antibody composed of a human immunoglobulin G1 (IgG1) monoclonal antibody
targeting human programmed death-ligand 1 (PD-L1) fused with a single chain variable
fragment (scFv) targeting 4-1BB (CD137; tumor necrosis factor receptor superfamily
member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic
activities. Upon administration, xirestomig simultaneously targets and binds to 4-1BB,
which is expressed on a variety of leukocyte subsets including activated T-lymphocytes,
and PD-L1 expressed on tumor cells. Upon PD-L1 binding, the 4-1BB activation signal
is induced and xirestomig acts as a conditional 4-1BB agonist in the tumor microenvironment
(TME), resulting in T-cell co-stimulation and enhances T-lymphocyte-mediated anti-tumor
activity. At the same time, xirestomig prevents PD-L1 from binding to and activating
its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This
abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances
cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor
growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival
of CD8-positive T-cells, suppresses the immune system and results in immune evasion.
4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is
an inducible costimulatory receptor that plays a key role in T-cell proliferation,
survival and cytolytic activity.;
UNII : Q2C2VG7V4N;
CAS number : 2756879-35-1;
Molecule name : ATG-101; ATG 101;
NCI Metathesaurus CUI : CL1798788;
Origin ID : C190124;
UMLS CUI : C5908101;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
